- In March 2026, Agilent Technologies received U.S. Food and Drug Administration approval for its PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic to identify esophageal or gastroesophageal junction carcinoma patients (CPS = 1) who may be eligible for Merck’s KEYTRUDA (pembrolizumab) combination therapy.
- This eighth KEYTRUDA-related indication for PD-L1 IHC 22C3 pharmDx strengthens Agilent’s role in precision oncology by broadening its companion diagnostic footprint across multiple hard-to-treat cancers where accurate biomarker testing is critical for treatment selection.
- We’ll now examine how this latest FDA companion diagnostic approval for KEYTRUDA in esophageal cancer could influence Agilent’s long-term investment narrative.
We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Agilent Technologies Investment Narrative Recap
To own Agilent, you need to believe in its role as a core lab partner across pharma, diagnostics, and applied markets, with a growing mix of consumables, services, and software. The new FDA approval for PD-L1 IHC 22C3 pharmDx in esophageal cancer reinforces Agilent’s precision oncology credentials, but does not materially change near term drivers, which still hinge on instrument replacement cycles and execution on cost and tariff mitigation, while competitive intensity and funding pressure in key end markets remain central risks.
The most relevant context for this approval is Agilent’s broader PD-L1 and digital pathology push showcased at the 2026 USCAP meeting, where it highlighted expanded biomarker testing and integrated pathology workflows. Together, the KEYTRUDA companion diagnostic indications and end to end pathology solutions feed into the same catalyst: expanding higher margin, recurring diagnostics and services revenue that can help balance exposure to more cyclical capital equipment spending.
Yet, against this progress, rising tariff driven costs and supply chain complexity remain a developing issue that investors should be aware of as...
Read the full narrative on Agilent Technologies (it's free!)
Agilent Technologies’ narrative projects $8.6 billion revenue and $2.0 billion earnings by 2029. This requires 6.6% yearly revenue growth and an earnings increase of about $0.7 billion from $1.3 billion today.
Uncover how Agilent Technologies' forecasts yield a $163.19 fair value, a 46% upside to its current price.
Exploring Other Perspectives
Five members of the Simply Wall St Community value Agilent between US$125.49 and US$163.19, underscoring how far opinions can diverge. You should weigh those views against Agilent’s growing precision oncology footprint, which could become increasingly important if core instrument replacement cycles slow or funding in key research markets tightens.
Explore 5 other fair value estimates on Agilent Technologies - why the stock might be worth as much as 46% more than the current price!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Agilent Technologies research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free Agilent Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agilent Technologies' overall financial health at a glance.
No Opportunity In Agilent Technologies?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Outshine the giants: these 21 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com